Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Relmada Therapeutics ( (RLMD) ) is now available.
Relmada Therapeutics reported its second-quarter 2025 financial results and announced promising 6-month follow-up data from its Phase 2 study of NDV-01 in non-muscle invasive bladder cancer (NMIBC), showing a 91% overall response rate. The company is preparing for a Phase 3 trial of NDV-01 and a Phase 2 study for sepranolone in Prader-Willi syndrome, reflecting its strategic focus on expanding its therapeutic pipeline.
The most recent analyst rating on (RLMD) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Relmada Therapeutics stock, see the RLMD Stock Forecast page.
Spark’s Take on RLMD Stock
According to Spark, TipRanks’ AI Analyst, RLMD is a Neutral.
Relmada Therapeutics’ overall score reflects its high-risk, high-reward profile typical of biotechnology firms in developmental stages. The company’s financial performance is weakened by zero revenue and significant cash burn, tempered by strong cash reserves. Strategic pipeline developments and recent acquisitions offer potential upside, but are countered by challenges such as discontinued projects and reliance on external financing. Technical analysis shows short-term momentum, but the overall outlook remains speculative.
To see Spark’s full report on RLMD stock, click here.
More about Relmada Therapeutics
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for oncology-related and central nervous system indications.
Average Trading Volume: 463,258
Technical Sentiment Signal: Sell
Current Market Cap: $18.89M
Find detailed analytics on RLMD stock on TipRanks’ Stock Analysis page.